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Objective: Insomnia can be broadly defined as difficulty initiating or maintaining sleep, or 
sleep that is not refreshing or of poor quality with negative effect on daytime function. Insom-
nia can be a primary condition or comorbid to an underlying disorder. Subjective measures of 
insomnia used in population studies, usually based on complaints of unsatisfactory sleep, put 
the prevalence at about 10%. Insomnia is more common in the elderly and in women, and is 
often associated with medical and psychiatric disorders. This review examines the measures 
used to assess quality of sleep (QOS) and daytime functioning and the impact of insomnia on 
society using these measures.
Methods: Literature searches were performed to identify all studies of insomnia (primary and 
comorbid) in adults (aged 18–64 years) and the elderly (aged $ 65 years) with baseline and/or 
outcomes relating to QOS or daytime functioning. The impact of poor QOS on quality of life 
(QOL), psychomotor and cognitive skills, health care resource utilization, and other societal 
effects was examined.
Results: Although definitions and measurement scales used to assess sleep quality vary widely, 
it is clear that the societal consequences of insomnia are substantial and include impaired QOL 
and increased health care utilization. The impact of poor QOS and impaired daytime function-
ing common in insomnia can lead to indirect effects such as lower work productivity, increased 
sick leave, and a higher rate of motor vehicle crashes.
Conclusions: Insomnia is associated with substantial direct and indirect costs to society. It is 
almost impossible to separate the costs associated with primary and comorbid insomnia. More 
studies are required which control for the severity of any primary disorder to accurately evalu-
ate the costs of comorbid insomnia. Development of standardized diagnostic and assessment 
scales will enable more accurate quantification of the true societal burden of insomnia and will 
contribute to greater understanding of this disorder.
Keywords: insomnia, quality of sleep, societal cost, quality of life, health care resource 
utilization
Introduction
Insomnia is a widely recognized term, which in its broadest definition indicates the 
presence of a complaint of unsatisfactory sleep associated with daytime functional 
impairment.1 Daytime functional impairment may include fatigue, irritability, anxiety, 
decreased ability to concentrate, and inability to perform complex tasks. A more specific 
definition of insomnia encompasses isolated sleep-related complaints (eg, difficulty 
falling or staying asleep, early awakening, or unrefreshing/nonrestorative sleep) when 
there is adequate opportunity for sleep.1Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Depending on the terminology used to define insomnia, 
the reported prevalence ranges from 4% to 50%.2–6 Recent 
estimates from an epidemiological survey carried out by 
Ohayon found that although insomnia is reported by nearly 
a third of the population, only 6%–15% are diagnosed 
with insomnia.7 With the more stringent clinical criteria of 
insomnia-related daytime impairment or distress, prevalence 
estimates are ∼10%.8 However, this may be an underestimate 
in view of current reports suggesting that only 1 in 20 patients 
suffering from insomnia seek treatment.9
Insomnia may present as the primary syndrome, or it 
may manifest as a symptom of another disease (comorbid 
insomnia). Primary insomnia refers to insomnia that has no 
attributable cause.10,11 Primary insomnia is estimated to occur 
in 25% of all chronic insomnia patients.11 Comorbid insomnia 
may be a symptom of an underlying problem such as pain, 
or physical or psychological disease.10,12 Both primary and 
comorbid insomnia are by definition associated with worse 
daytime functioning.10,13
Insomnia commonly occurs in patients with psychiatric 
symptoms, although it is difficult to ascertain whether insom-
nia is caused by or is a cause of the psychiatric disorder. 
Epidemiological data from more than 10,000 patients demon-
strate the co-occurrence of sleep-related complaints and psy-
chiatric disorders, primarily depression and anxiety, in ∼40% 
of patients; however, study data indicate that the incidence of 
psychopathology in patients with chronic insomnia may be as 
high as 62%.14 Older age and female gender appear to confer 
a greater risk of insomnia,15,16 and comorbid medical condi-
tions are reported to contribute to the significantly increased 
prevalence of insomnia in the elderly.5,17–19 A study by 
Ohayon and Roth investigated the psychiatric history of 
insomniac subjects in the general population. A total of 
14,915 subjects aged from 15 to 100 years who were repre-
sentative of the general population of the United Kingdom, 
Germany, Italy, and Portugal were interviewed by telephone 
using the Sleep-EVAL system. The questionnaire assessed 
current psychiatric disorders according to the Diagnostic 
and Statistical Manual of Mental Disorders, Fourth Edition 
(DSM-IV) classification, and a series of questions assessed 
the psychiatric history. Insomnia was considered as chronic 
if it lasted for 6 months or more. The prevalence of insomnia 
associated with impaired daytime functioning was 19.1% 
and significantly increased with age. More than 90% of 
these subjects had chronic insomnia. Approximately 28% 
of subjects with insomnia had a current diagnosis of mental 
disorder and more than 25% of subjects had a psychiatric 
history. Presence of severe insomnia, diagnosis of primary 
insomnia or insomnia related to a medical condition, and 
insomnia that lasted more than 1 year were all predictors of 
a psychiatric history.13
The societal consequences of insomnia are reported to be 
substantial and include impaired quality of life (QOL) and 
an increased risk of falls and hip fractures, both of which 
lead to increased health care utilization.20,21 Furthermore, the 
impact of sleep disorders on everyday life results in lower 
work productivity (presenteeism) as well as absenteeism.21 
Primary chronic insomnia in particular has been shown to 
be associated with a range of effects, including reduced 
productivity, daytime dysfunction, poor health-related (HR) 
QOL, and increased direct and indirect costs.22
Despite being a key characteristic of insomnia, and one 
which is used as a measure of insomnia in clinical studies, 
the widely used term ‘sleep quality’ is poorly defined and 
not fully understood.23
This review aims to assess the evidence associated with 
primary and comorbid insomnia in both adult and elderly 
populations specifically regarding measures of quality of 
sleep (QOS) and daytime functioning and review the impact 
of these specific aspects of insomnia on QOL. The impact 
of these effects on psychomotor and cognitive skills, health 
care resource utilization, and absenteeism/presenteeism will 
also be discussed.
Search methodology
A literature search was conducted to retrieve articles on the 
societal cost of insomnia. Key word searches were conducted 
in BIOSIS Previews, EMBASE, Cochrane Collaboration, 
and Medline databases using the Ovid platform. The key 
search terms used were insomnia (title or key words), QOL, 
cost/costs, productivity, absenteeism, family, social life, 
sleep quality/QOS, alertness, psychomotor, and cognitive. 
Studies that did not include patients with either primary or 
comorbid insomnia or those that did not report the required 
baseline or outcome data were excluded. Studies chosen 
were separated into those studying primary and comorbid 
insomnia. In order to gain an accurate estimate of the impact 
of insomnia itself, the comorbid insomnia studies were then 
further separated into those in which specific effects/costs 
relating to insomnia alone were clearly defined and those in 
which the insomnia effects/costs were not clearly defined 
and/or could not be separated from those relating to the 
primary condition. Because any review of societal impact of 
insomnia is dependent on the accuracy and clinical relevance 
of the methods used to assess the condition, an appraisal of 
the diagnosis and measurement of insomnia, in particular, the Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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scales used to assess sleep quality and daytime functioning 
was performed.
Diagnosis and measurement
Sleep quality and daytime functioning
Sleep quality is not synonymous with sleep quantity, and 
the difficulty of objectively defining and measuring QOS is 
widely acknowledged. Indeed, patients can report poor QOS 
despite receiving adequate hours spent sleeping. Within the 
field of sleep medicine, there has been a transition from a 
strong focus on sleep quantity toward a greater recognition 
of the importance of sleep quality. This is indicated by the 
increasing number of publications evaluating sleep quality. 
A cross-sectional study determined that patients with insom-
nia and normal sleepers had a broadly similar understanding 
of the meaning of sleep quality, which included tiredness 
on waking and throughout the day, the number of night 
awakenings and feeling rested or restored on wakening.23 
These findings suggest that a comprehensive assessment 
of sleep quality should include both waking and daytime 
variables and a comparison of subjective versus objective 
sleep measures.
A recent review evaluating instruments for the assessment 
of sleep dysfunction found that the numerous patient-reported 
assessment measures for the identification and evaluation 
of sleep dysfunction have significant variability in their 
interpretability and applicability and most did not include all 
four domains of interest: sleep initiation, sleep maintenance, 
sleep adequacy, and somnolence. Such measures include the 
Functional Outcomes of Sleep Questionnaire, Quality of Life 
in Insomniacs, and the Sleep–Wake Activity Inventory.24 
The wide availability of these instruments has resulted in a 
lack of consistency regarding diagnostic, baseline, and out-
come measures within the published literature, which limits 
the comparison between studies of patients with insomnia.
Only one instrument, the Pittsburgh Sleep Quality Index 
(PSQI), has been psychometrically evaluated and provides 
useful information on interpretability.24 This retrospective 
instrument assesses sleep patterns and sleep satisfaction over 
the last 4 weeks. The PSQI is widely used and has a global 
score range of 0–21; a global score .5 generally denotes 
poor subjective sleep quality.25,26
Measures of daytime dysfunction are included in the 
more comprehensive sleep quality indices such as PSQI25 and 
health-related quality of life (HR-QOL) instruments such as 
Medical Outcomes Study 36-item Short-Form Health Survey 
(MOS SF-36).27 However, some studies perform separate 
assessments of daytime function, using subjective daytime 
somnolence scales such as the Epworth Sleepiness Scale 
(ESS),10,28,29 or the Insomnia Impact Scale (IIS) questionnaire 
evaluating occupational, physical, cognitive, emotional, and 
social aspects of daytime dysfunction.10 Twenty-four-hour 
actigraphy provides an objective measure that may reflect 
daytime function.29–32 Actigraphs have become popular as 
a reliable and cost-effective objective measure of nocturnal 
activity and also have the advantage of measuring nocturnal 
events in the individual’s natural sleep environment.
In 2006, an expert panel of 25 researchers reviewed the 
literature on insomnia assessment and recommended the 
adoption of standard diagnostic scales for primary insomnia 
to facilitate comparison of data among studies.1 Three key 
areas were identified: 1) definitions/diagnosis of insomnia and 
comorbid conditions, 2) measures of sleep and insomnia, and 
3) measures of waking correlates and consequences of insomnia 
disorders (eg, daytime fatigue, sleepiness, mood, performance, 
and QOL). Recommended standard diagnostic, epidemiological, 
and coding resources for clinicians and researchers for insomnia 
included the International Classification of Sleep Disorders 
2nd Edition (ICSD-2) and the Research Diagnostic Criteria 
for Insomnia (RDC-I) criteria for clinical history taking and 
questionnaire format and content. The panel also identified the 
need for a standardized sleep diary, and neurobehavioral and 
cognitive measures sensitive to deficits caused by insomnia.1 The 
development and validation of these tools will allow research-
ers to compare different studies and provide a more accurate 
assessment of the societal costs of insomnia.
QOL
QOL measures provide a valuable assessment of the effect of 
chronic insomnia on patients’ daily lives. However, debate 
continues regarding the definition of QOL and, in particular, 
HR-QOL.24 Vague undefined terms such as ‘health status’ 
and ‘well-being’ are often used interchangeably to describe 
QOL. Most insomnia studies evaluating HR-QOL use the 
MOS SF-36.27–29,31,33–38 Other tools used in clinical studies 
assessing the impact of insomnia on HR-QOL have included the 
Nottingham Health Profile (NHP),39 the Quality of Life Index 
(QLI),40 the EuroQoL-5D,41 the WHO-5 Well-being Index,42 
and in comorbid insomnia, a variety of other more specialized 
QOL scales tailored to specific primary disorders.37,43,44
Clinical studies of insomnia
Having addressed the potential pitfalls of any evaluation of 
studies assessing sleep quality and QOL, a meaningful objec-
tive review of the published literature can be done, bearing 
in mind these limitations.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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A discussion of cognitive behavioral therapy (CBT) and 
pharmacotherapy for the treatment of insomnia was beyond 
the scope of this review. However, many of the clinical 
studies evaluating various treatment options for primary and 
comorbid insomnia provide data on baseline QOS and/or 
daytime functioning and the impact of insomnia on QOL. 
A total of 243 English language clinical studies were identi-
fied by the literature searches. Of those, 49 clinical studies 
included patients with either primary or comorbid insomnia, 
and reported QOS, daytime dysfunction, QOL baseline data, 
or data on direct or indirect impact/costs of insomnia. For the 
purpose of this review, studies were divided into studies with 
primary insomnia cohorts (n = 28; Tables 1 and 2), studies 
in patients with comorbid insomnia in which the effects of 
insomnia were clearly defined and/or could be separated from 
those relating to the underlying condition (n = 6; Table 3), and 
studies of patients with comorbid insomnia in which the costs 
relating to insomnia and the primary condition could not be 
clearly separated/defined (n = 15; Table 4). In addition, five 
population-based studies were identified that also provided 
data on QOS, daytime dysfunction, and QOL in patients with 
insomnia (Table 5).
Primary insomnia
QOS and daytime functioning
Experts concur that patients with primary insomnia have 
poor QOS compared with good sleepers and that the severity 
of insomnia is linked with subjective sleep quality.56,57 
Data from clinical studies (Table 1) indicate that patients 
with primary insomnia generally experience poor baseline 
QOS as assessed using a variety of measures including 
PSQI, structured questionnaires, questionnaires using 
a Likert scale or visual analog scale (VAS), and sleep 
diaries.32,33,42,45–47,49–51,53–57,59–62
In a double-blind, placebo-controlled study in 702 patients 
with chronic primary insomnia,61 in addition to reduced QOS 
(mean QOS 4.4 on 7-point Likert scale), some impair-
ment in daytime function, assessed using the patient-rated 
Insomnia Severity Index (ISI) impact subscale, was seen in 
63.8%–65.2% of patients prior to treatment.61
Many  of  the  published  studies  are  in  elderly 
cohorts.34,47–49,51,53,55 A study in 229 elderly patients (65–85 years) 
showed that 30% subjectively rated their sleep quality 
as extremely poor.55 Another study in a similar population 
(60–83 years) showed that contrary to expectations, daytime 
napping common in this age group did not adversely impact 
nocturnal sleep quality, but in fact, significantly improved 
global sleep quality and sleep efficiency.51
Lichstein et al compared patients with primary and 
comorbid insomnia and found that there was little differ-
ence in subjective reported QOS and daytime functioning 
between the two types of insomnia, and that QOS and daytime 
functioning appear to be independent, with daytime sleepi-
ness more common in elderly patients with insomnia than 
in age-matched noninsomniacs.10
QOL
HR-QOL is a major endpoint in many clinical studies evaluat-
ing treatment for insomnia, with most studies using the MOS 
SF-36 scale for evaluating HR-QOL. The baseline QOL 
parameters of patients with primary insomnia enrolled in 
clinical trials (Table 1) show that, prior to treatment, patients 
have markedly impaired QOL.27,33,34,38–40
Zammit et al38 confirmed that in patients with primary 
insomnia, QOL was reduced across multiple domains 
relative to individuals with no sleep complaints. Signifi-
cant reductions (P , 0.0001) were observed on all MOS 
SF-36 subscales including body pain, general and mental 
health, emotional, physical and social functioning, and 
vitality.38 An assessment of recreation time revealed that 
patients with insomnia watch more television, and read 
and exercise less than patients without insomnia. In this 
cohort, patients with insomnia also reported a higher degree 
of depression and anxiety than those without insomnia 
(P , 0.0001).38 Philip et al showed that a subgroup of 
adults with primary insomnia had lower QOL than matched 
controls without insomnia, as demonstrated by higher 
scores on all six NHP dimensions (emotional reaction, 
energy, pain, social isolation, sleep, and physical mobility; 
P , 0.001 for all).39 In an investigation of subjective 
HR-QOL in 100 patients with disturbed sleep referred to 
a sleep laboratory,40 HR-QOL (assessed using the QLI) 
was significantly reduced in patients with disturbed sleep 
(assessed using objective (polysomnographic) and subjec-
tive (psychometric) QOS and awakening scales), with a 
more pronounced reduction of HR-QOL in nonorganic 
than in organic sleep disturbance. Seven of the 10 HR-QOL 
components (physical well-being, psychological well-
being, self-care and independent functioning, occupational 
functioning, interpersonal functioning, personal fulfillment, 
and overall QOL) were significantly lower.40
Psychomotor and cognitive skills
Few studies have investigated the association between 
primary insomnia and cognitive or psychomotor impairment 
and the available data are contradictory. In one study, patients Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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with primary insomnia aged 18–75 years (n = 362) were 
found to have reduced attention, concentration, memory, 
reasoning and problem solving, and reaction time relative 
to those without insomnia as measured by the Medical Out-
comes Study Cognitive Scale.38
Bastien et al demonstrated that patients aged $55 years 
who complained of insomnia and poor sleep quality, but were 
measured objectively as having good sleep, demonstrated 
better daytime functioning and cognitive performance than 
those measured objectively as having poor sleep,77 showing 
that cognitive performance appears to correlate better with 
objective sleep measures than with subjective assessment 
of sleep quality.
However, Haimov et al reported that in 64 elderly 
patients with primary insomnia, both subjective and objective 
measures were in agreement, and those with insomnia had 
significantly reduced memory span, executive functioning, 
and impaired cognitive performance, compared with 35 age-
matched controls.78 This decline in cognitive performance 
may be due to an age-related decline in visual perceptual 
processing, which appears to be worsened by insomnia.48 
Interestingly, elderly patients with insomnia with relative 
slow-wave sleep deficits also demonstrated slower reaction 
times compared with age-matched patients with insomnia 
without these specific sleep deficits.79 The investigators 
concluded that patients with slow-wave deficits might 
represent a specific subtype of insomnia, perhaps those 
with daytime functional impairment, although this was not 
explored further.
Health care resource utilization
Insomnia is associated with a substantial direct (eg, out-
patient visits, medications, and hospitalizations) and 
indirect (eg, lost productivity and accidents) burden on 
society.80 However, it is difficult to estimate the cost of 
insomnia accurately, given the differences in underlying 
assumptions made by researchers and health economists: 
there is limited data quantifying these effects, estimates 
have varied widely depending on the specific costs 
included, and few estimates clearly distinguish primary and 
comorbid insomnia. QOL appears to have a major impact 
on health care resource use, but much of the QOL data 
is cross-sectional and cannot show whether associations 
are causal.80 US-based studies report varying estimates 
on the total cost of insomnia from a societal perspective. 
In a study conducted in 1995, direct costs were estimated 
to be approximately US$14 billion with 91% of these 
costs attributable to nursing home care.81 The cognitive Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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Wade
impairment associated with insomnia and the increased risk 
of falls and hip fractures contribute to greater utilization 
of nursing home facilities.81 The principal reason given by 
relatives for admitting an elderly person to an institution is 
insomnia.82 This is particularly true of those with dementia 
where relatives or caregivers cannot cope with nighttime 
disturbances. The cost of care in these patients is therefore 
due to both dementia and insomnia, but studies evaluating 
the costs of insomnia do not explain how overlapping costs 
such as these are assigned.
A recent analysis specifically estimated costs in patients 
with primary insomnia, utilizing a decision analytical model 
from a broad payer and societal perspective. The total per-
patient direct medical costs in the 6 months prior to treatment 
or diagnosis for chronic primary insomnia (n = 16,757) were 
almost twice as high as the matched control group (US$4565 
versus US$2757).22
Treatment costs
Given that a significant proportion of patients with insomnia 
choose to self-medicate, actual treatment usage and treatment 
costs are difficult to determine. A survey by Leger et al found 
that 10% of patients with insomnia (not defined as primary 
or comorbid) used over-the-counter (OTC) medications in 
an effort to promote sleep.17 Patients with severe insomnia 
have a higher rate of noninsomnia medication use compared 
with individuals who are good sleepers, particularly with 
regard to cardiovascular, urogenital, and gastrointestinal 
drugs.17,35 There is also a greater use of hematological and 
radiological resources in those with insomnia versus good 
sleepers.17,35 However, the bulk of increased resource use and 
costs in these studies probably reflect costs associated with 
the primary disorder being treated, rather than insomnia.
Direct medical costs of insomnia in the United States 
have been estimated to be as high as US$13.9 billion annu-
ally, and indirect costs have been estimated to range from 
US$77 to US$92 billion annually.80 Treatment-related costs 
were reported to comprise approximately US$2 billion 
of the total direct costs associated with insomnia (1995 
values).4,80 These costs can be divided into prescription 
(US$809 million) and nonprescription medications, includ-
ing the use of alcohol as a sleep aid (US$780 million), 
OTC sleep remedies (US$325 million), and melatonin 
(US$50 million).80 A second analysis, using 1994 val-
ues, estimated the largest direct cost of sleep aids to be 
alcohol (US$574 million) followed by benzodiazepines 
and anxiolytics (US$455 million), and OTC medication 
(US$84 million).80
Botteman et al developed a decision analytical model22 
based on 6-month sleep efficacy data from study in 
800 patients with primary insomnia (median age 44 years) 
(n = 800),83 HR-QOL data from patients with and without 
comorbid insomnia (mean age 54 years) (n = 3445),74 and 
costs from a retrospective analysis of insomnia patients 
pre- and post-treatment costs age-matched to efficacy data. 
Using this model, the total direct medical cost attributed 
to untreated primary insomnia in 6 months versus costs in 
individuals without insomnia was US$1453 per person after 
adjustment for potential confounders (.50% higher than 
those without insomnia) and the total indirect cost in 6 months 
(absenteeism and presenteeism) was US$1091 per person.22 
This study is one of the few to isolate both the indirect and 
Table 2 economic studies showing the costs of primary insomnia
Study  
reference
Data used in model Baseline insomnia  
diagnosis/assessment
Sleep endpoints  
used
Assumptions Economic outcomes
22 Sleep efficacy data from  
study in patients with  
primary insomnia; median  
age 44 (25–69 years)  
(n = 800) (67) 
HR-QOL data  
from patients with and  
without comorbid insomnia;  
mean age 54 years  
(n = 3445) (68) 
Costs from a retrospective  
analysis of insomnia patients;  
pre- and post-treatment costs  
age-matched to efficacy data
DSM-iv , 6.5 h  
sleep/night and/or sleep  
latency .30 min
Sleep latency, total  
sleep time,  
awakenings, wake  
time after sleep  
onset, subjective  
QOS and daytime  
functioning rating,  
alertness, physical  
well-being, HR-QOL  
(Q-LeS-Q)
Presenteeism:  
assumed 5%  
reduction in  
work  
productivity
Total direct medical cost  
attributed to untreated  
insomnia in 6 months =  
US$1453 per person after 
adjustment for potential 
confounders 
Total indirect costs in  
6 months (absenteeism  
and presenteeism) =  
US$1091 per person 
(both versus  
individuals without  
insomnia)
Abbreviations: DSM-iv, Diagnostic and Statistical Manual of Mental Disorders, Fourth edition; QOS, quality of sleep.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Table 3 Clinical studies evaluating QOS and/or daytime functioning and/or QOL in patients with comorbid insomnia
Study 
reference
Patient  
population
Baseline insomnia  
diagnosis/assessment
Assessment  
scales used
QOS and QOL baseline  
measures and other outcomes
28 Chronic heart  
failure (n = 223)
No formal baseline  
assessment of insomnia
USi-CHF, eSS,  
MOS SF-36, MLWHF  
Questionnaire
HR-QOL, measured by SF-36, was reduced in patients 
with heart failure versus the general population  
aged $ 75 years, for all dimensions except bodily pain  
(P , 0.05). Heart failure patients with difficulty  
initiating and maintaining sleep and early-morning 
awakenings had the worst HR-QOL, particularly  
for general health, vitality, and social functioning
30 Recovering  
alcoholics (n = 60)
DSM-iv, sleep-onset latency 
.30 min for $3 nights/week
PSQi global score Sleep quality ranged from 12.4 to 13.3
36 Patients on  
hemodialysis  
(n = 89)
No formal baseline  
assessment of insomnia
MOS-SF-36, PSQi ‘Poor sleepers’ had a reduced QOL across all domains, 
and mental and physical component scores were 
inversely correlated with sleep quality (P , 0.01)  
71% of this patient cohort were ‘poor sleepers’  
(global PSQi . 5)
63 Cancer  
patients  
(n = 954)
eORTC-QLQ-C30 insomnia  
subscale
Ferrans and  
powers QLi
insomnia was strongly related to the health and 
physical functioning aspects of QOL. A 30-point 
increase in QLQ-C30 was associated with  
a 2.01-point reduction in health and physical 
functioning and a 1.3-point reduction in psychological 
and spiritual functioning
37 Renal transplantation  
(n = 1067)
AiS KDQOL-SF  
(including MOS  
SF-36)
The presence of restless legs syndrome was associated 
with a threefold increase in insomnia (P = 0.001), and 
was independently associated with impaired HR-QOL. 
Physical and mental aspects of QOL were significantly 
reduced in patients with restless legs syndrome versus 
those without (P # 0.01)
44 Inactive inflammatory  
bowel disease  
(n = 119)
Patients with sleep  
disorders were excluded
iBD QOL  
Questionnaire  
PSQi
QOL was inversely correlated with sleep  
quality. Analysis of the psychosocial component  
score revealed more anxiety in patients  
with iBD versus controls  
iBD patients had prolonged sleep latency, frequent 
sleep fragmentation, reduced daytime energy, higher 
usage of sleeping medications, and poor overall sleep 
quality versus patients with inflammatory bowel 
syndrome and healthy controls
Abbreviations:  QOS,  quality  of  sleep;  QOL,  quality  of  life;  USi-CHF,  Uppsala  Sleep  inventory-Chronic  Heart  Failure;  eSS,  epworth  Sleepiness  Scale;  MOS  SF-36, 
Medical Outcomes Study 36-item Short-Form; MLWHF, Minnesota Living with Heart Failure; DSM-iv, Diagnostic and Statistical Manual of Mental Disorders, Fourth edition;   
PSQi, Pittsburgh Sleep Quality index; eORTC-QLQ, european Organization for Research Treatment of Cancer-Quality of Life Questionnaire; QLi, Quality of Life index;   
AiS, Athens insomnia Scale; KDQOL-SF, Kidney Disease QOL-SF.
direct costs of untreated primary insomnia from those associ-
ated with comorbidities.
visits to health care professionals
The Leger et al survey reported that patients with severe 
primary insomnia visited either a primary care physician or a 
specialist more frequently than individuals who were normal 
sleepers, irrespective of the reason for the visit.17 Again, this 
study, while attempting to exclude patients with anxiety and 
depression, failed to differentiate primary from secondary 
insomnia, with the majority of recorded visits being for a 
primary physical complaint.
Absenteeism/presenteeism
A recent analysis reported a decreased QOL and a higher 
rate of absenteeism among patients with insomnia compared 
with those without insomnia;39 however, multivariate analysis 
indicated that increased absenteeism was significantly more 
frequent only in patients with insomnia who also self-reported 
depressive feelings and not in those with primary insomnia 
without depressive feelings.39 These findings are at odds with 
those of Leger et al52 who reported approximately double the 
rate of absenteeism (odds ratio 1.93; P , 0.001) irrespec-
tive of comorbid conditions, in a sample of 369 patients 
with chronic insomnia compared with 369 age-matched Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Table 4 Clinical studies evaluating QOS and/or daytime functioning and/or QOL in patients with comorbid insomnia (studies in which 
the insomnia effects could not be distinguished from those associated with the primary condition)
Study  
reference
Patient population Baseline insomnia  
diagnosis/assessment
Assessment  
scales used
QOS and QOL baseline measures 
and other outcomes
64 Long-term hemodialysis  
(n = 700)
PSQi, eSS PSQi Two-thirds of this cohort had a PSQi 
score .5; gender had no impact on 
PSQi score
65 Hepatitis C virus,  
decompensated liver  
disease, and interferon  
α2b plus ribavirin (n = 53)
No formal baseline  
assessment
SQP Mean SQP score of 4.7; 66% of  
patients reported $3 symptoms  
of disturbed sleep
66 Chronic pain (n = 60) DSM-iii/DSM-iv PSQi global score Sleep quality was 13.6–14.2
67 Chronic pain (n = 51) DSM-iv PSQi global score Sleep quality was rated as 13.8
69 Psychiatrically ill  
patients (n = 48)
Diagnostic criteria  
not reported
Self-reported sleep  
quality (5-point scale;  
0 = no problem to  
4 = very much a problem)
Sleep quality rated as 2.5
69 Breast cancer  
survivors (n = 14)
Trouble sleeping on 28/7  
nights, poor daytime functioning  
affecting physical well-being,  
emotions, ability to concentrate,  
ability to carry out usual  
activities or cope with stress
Sleep diary (5-point  
scale; 5 = good sleep)
Sleep quality rated as 2.9
43 Breast cancer  
survivors (n = 72)
DSM-iv, iCD-10 FACT-B Global assessment ranged from 108.5 
to 109
31 Fibromyalgia (n = 42) Structured interview criteria  
for insomnia and $1 h of  
nocturnal wake time over  
1 week of sleep log monitoring
MOS SF-36 Mental health composite score ranged 
from 46.1 to 51.3
35 Good sleepers  
(n = 1867), level i  
insomnia (n = 464),  
level ii insomnia  
(n = 1116)
HSQ and MOS SF-36 Sleep-loss  
category items (level i = difficulty  
attaining or maintaining sleep,  
level ii = level i with daytime  
dysfunction)
HSQ 
MOS SF-36
Level ii insomnia associated with 
significantly lower scores in all domains 
versus noninsomnia. Scores for level i 
insomnia were lower but not significant 
Level ii but not level i insomnia 
associated with more physician and 
eR visits, calls to physician, and OTC 
medications versus noninsomnia 
Both level i and ii insomnia associated 
with more laboratory tests and drug 
prescriptions than noninsomnia
70 Major depressive  
disorder (n = 12)
PSQi PSQi global score Sleep quality rated as 15 (range 9–19)
41 Cancer patients  
with depression (n = 42)
C-LSeQ C-LSeQ (5-point Likert  
scale; lower score = better  
sleep) euroQoL-5D (lower  
score = better QOL)
Mean QOS rated as 4.3  
QOL: Mobility 2.0; self-care  
1.8; pain/discomfort 2.1
29 Lung cancer outpatients 
(n = 29)
No formal baseline assessment  
of insomnia
MOS SF-36
PSQi, eSS, night-time  
wrist actigraphy
Patients with lung cancer had a negative 
correlation between the mental and 
physical (P = 0.004) components of the 
SF-36 and sleep time  
Patients with lung cancer had a worse 
QOS (PSQi: 9.6 versus 5.6; P , 0.001), 
lower sleep efficiency (P = 0.002), 
higher sleep fragmentation (P = 0.002), 
and greater excessive daytime 
sleepiness (eSS: 8.6 versus 5.6; P = 0.0) 
than age-matched noncancer patients 
with treated sleep apnea
(Continued )Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Table 4 (Continued)
Study  
reference
Patient population Baseline insomnia  
diagnosis/assessment
Assessment  
scales used
QOS and QOL baseline measures 
and other outcomes
71 Major depressive  
disorder (n = 332)
PSQi PSQi global score Sleep quality was rated as 12.0–12.5
72 Assisted living geriatric  
residents, 58–104 years  
(n = 188)
effect of sleep (insomnia  
and daytime sleepiness)  
on cognitive and physical  
function
SQ (QOS)  
MMSe, NPi, CSDD  
(psychiatric and  
neurological status)  
PGDRS (physical daily  
living function) GMHRS  
(general medical health)
Subjects with insomnia had similar use 
of most antidepressants but higher use 
of hypnotics and sedatives than those 
without insomnia  
Subjects with and without impaired 
daytime function had similar use of all 
medications Subjects with insomnia 
only had better cognitive and physical 
function than those without insomnia 
(no insomnia or daytime dysfunction or 
daytime dysfunction only) Subjects with 
daytime dysfunction only had worse 
cognitive and physical function than 
those without daytime dysfunction  
(no insomnia or daytime dysfunction  
or insomnia only)
73 Patients with  
depression (n = 16)
insomnia-related items  
on the Hamilton Depression  
Rating Scale with a  
total score of $3
Self-reported subjective  
estimates of sleep quality
Mean subjective sleep quality  
rated as 1.8
12 Anxiety disorders  
(n = 22)
Sleep eligibility criteria  
not reported
PSQi global score Mean sleep quality was rated as 5 
(range 2–10)
Abbreviations: QOS, quality of sleep; QOL, quality of life; PSQI, Pittsburgh Sleep Quality Index; ESS, Epworth Sleepiness Scale; SQP, Sleep Quality Profile; DSM-IV, Diagnostic 
and Statistical Manual of Mental Disorders, Fourth Edition; ICD, International Classification of Diseases; FACT-B, Functional Assessment of Cancer Therapy-Breast; MOS SF-36, 
Medical Outcomes Study 36-item Short-Form; HSQ, Health Status Questionnaire; SQ, Sleep Questionnaire; C-LSeQ, Chonnam National University Hospital-Leeds Sleep 
evaluation Questionnaire; MMSe, Mini-Mental State examination; NPi, Neuropsychiatric inventory; CSDD, Cornell Scale for Depression in Dementia; PGDRS, Psychogeriatric 
Dependency Rating Scale – Physical subscale; GMHRS, General Medical Health Rating Scale.
good sleepers. This study also reported that insomnia was 
associated with poor self-esteem, lower job satisfaction, and 
lower efficiency.52 Although the Leger et al study52 excluded 
patients who had at least 3 months continual absence from 
work for a chronic physical condition, it is possible that the 
majority of the remaining patients may still have had comor-
bid insomnia.
The economic consequences associated with reduced 
work performance due to insomnia (presenteeism) are 
significant and may be more than those associated with sick 
leave/absenteeism. A decision analytical model in adults 
with chronic primary insomnia reported that the total cost of 
insomnia due to reduced performance at work was US$860, 
and the cost due to total lost productivity (absenteeism and 
presenteeism) was US$1091 per person over a 6-month 
period.22
Other indirect societal costs
Primary insomnia is also associated with a higher motor   
vehicle crash rate and a threefold greater risk of having two or 
three serious road accidents compared with matched controls.52 
A French-based modeling analysis, involving a hypotheti-
cal cohort of 100,000 adult drivers with insomnia (primary 
or comorbid), suggested that it is the treatment for sleep 
disorders and not the sleep impairment itself that increases 
the risk of vehicle crashes; the analysis found that the 
choice of sleep medication influenced the crash rate and 
that treatment with zopiclone, but not zaleplon, resulted 
in 503 extra crashes per 100,000 drivers over a 14-day 
period.84
Comorbid insomnia
Most clinical and economic studies of insomnia include a 
high proportion of individuals with comorbid insomnia, even 
those purporting to be primary insomnia studies discussed 
in the previous section. This makes it very difficult to assign 
specific resource use and estimate the weighting of other 
factors affecting cost, to the insomnia alone.
QOS and daytime functioning
A number of studies have investigated the impact of poor 
QOS in patients with comorbid insomnia, although for many Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Table 5 Population-based studies measuring QOS, daytime functioning, and QOL in patients with insomnia
Study reference Patient population Baseline insomnia  
diagnosis/assessment
QOS and QOL  
scales used
QOS and QOL outcomes
20 Women aged  
70–75 years  
(n = 10,430)
Nottingham health  
profiles 5-item sleep  
subscale
SF-36 63% of the cohort reported 
$1 items related to sleeping 
difficulties. Sleeping impairment 
was negatively related to 
physical functioning, bodily pain, 
vitality, social functioning, and 
general mental health domains 
(P , 0.0001)
74 Chronic illness  
(n = 3445)
MOS SF-36 SF-36 Mild to severe insomnia was 
reported in 50% of patients. 
insomnia was independently 
associated with impaired HR-
QOL, which was diminished 
across all SF-36 domains, 
particularly mental and general 
health perceptions, and vitality
75 Population-based  
cohort (n = 953)
DSM-iv-TR, iCD-10, iSi,  
PSQi, utilization of  
sleep-promoting medications
SF-12 Health  
survey
47.4% of the cohort had insomnia 
syndrome or insomnia symptoms. 
Patients with insomnia syndrome 
have a poorer HR-QOL across 
all SF-12 domains than patients 
with insomnia symptoms without 
impaired daytime functioning 
who have a worse HR-QOL than 
good sleepers
76 Older adults  
(n = 2800)
Questionnaire: difficulty getting  
to sleep, waking up at night,  
difficulty getting back to sleep,  
and repeated night waking
SF-36 49% of the cohort reported 
$1 insomnia trait. Mental and 
physical SF-36 scores significantly 
decreased (P = 0.0001) as the 
number of insomnia traits 
increased
Abbreviations: QOS, quality of sleep; QOL, quality of life; MOS SF-36, Medical Outcomes Study 36-item Short-Form; DSM-iv-TR, Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition, Text Revision; ICD, International Classification of Diseases; ISI, Insomnia Severity Index; PSQI, Pittsburgh Sleep Quality Index.
of these studies, it was not possible to determine whether the 
impact on QOL, resource, and other individual and societal 
effects was due to entirely poor insomnia, or whether the 
underlying primary disorder was also a factor. As seen in 
patients with primary insomnia, patients with comorbid 
insomnia relating to comorbid conditions such as cancer,29 
hepatitis C,65 and renal patients on hemodialysis36,64 report 
poor baseline sleep quality compared with their healthy 
counterparts (Tables 2 and 3).
In some of these studies, it was not possible to tell 
whether the sleep quality and daytime functioning were 
secondary to the primary disorder or an adverse effect of 
treatment. For example, patients with insomnia comorbid to 
newly diagnosed lung cancer29 had lower QOS and greater 
daytime sleepiness than matched patients without sleep 
disturbances or lung cancer. Therefore, it was not possible 
to tell whether the QOS and daytime sleepiness were due 
knowledge of the cancer, cancer symptoms, or whether they 
were side effects of the medications used to treat the lung 
cancer. In the study by Iliescu et al in 89 patients receiving 
renal hemodialysis in which 71% were categorized as poor 
sleepers, the authors commented that poor sleep is common 
in hemodialysis patients, but that end-stage renal disease 
also has a direct impact on sleep quality.36
QOL
As in case of patients with primary insomnia, comorbid 
insomnia reported in patients with medical conditions such 
as chronic heart failure,28 inflammatory bowel disease,44 
cancer,29,63 and those receiving hemodialysis,36 has a negative 
effect on HR-QOL (Tables 2 and 3). The baseline param-
eters of patients with comorbid insomnia enrolled in clinical 
trials evaluating various treatment options show markedly 
impaired QOL at baseline. Patients experiencing difficulty Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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initiating and maintaining sleep, and those with early-
morning awakenings and excessive daytime sleepiness, had 
the most impaired QOL.28
Iliescu et al36 showed an association between QOS (PSQI) 
and HR-QOL (MOS SF-36) in 89 hemodialysis patients 
independent of known predictors of reduced HR-QOL. 
In the 71% of subjects who were poor sleepers, the SF-36 
mental component summary (MCS) and physical component 
summary (PCS) correlated inversely with the global PSQI 
score (P , 0.01 for both). Although it was not possible 
to tell whether sleep quality was affected by medication, 
a multivariate analysis showed that the PSQI score was a 
significant independent predictor of QOL after adjustment 
for age, sex, hemoglobin, serum albumin, comorbidity, and 
depression.36
In a study reporting the prevalence of insomnia and its 
impact on patients’ HR-QOL and health care resource use 
in managed-care settings in the United States (n = 1707),35 
those with level II insomnia (poor sleep quality plus daytime 
dysfunction) had significantly lower MOS SF-36 scores 
than those without insomnia or those with insomnia with no 
reported daytime dysfunction (level I insomnia). The lack 
of impact of level I insomnia on HR-QOL attributable to the 
absence of daytime dysfunction in these individuals supports 
previous observations that the most serious consequence of 
insomnia is the loss of well-being during the day rather than 
loss of sleep itself.35
Psychomotor and cognitive skills
Sleep disturbance is very common among the elderly and in 
a study of elderly residents in an assisted living setting: the 
goals were to estimate the prevalence, types, and correlates 
of sleep disturbance in assisted living and to examine the 
relationship between sleep disturbance and assessments of 
cognitive and functional domains, independent of medical 
comorbidity, depression, or medication use. The hypothesis 
was that sleep disturbance, specifically daytime sleepiness 
and/or insomnia, would be independently associated with 
decreased cognitive functioning and decreased functioning in 
activities of daily living. The prevalence of ‘sleep disturbance’ 
(including insomnia, daytime sleepiness, excessive dreams, 
and/or long duration of sleep problem) was 69%; this is simi-
lar to rates in nursing homes (70%) and higher than reported 
in a community setting (50%).72 Insomnia was not defined as 
primary or comorbid in this study, but most patients had med-
ical and psychological disorders. Of the sample which met the 
criteria for ‘any sleep disturbance’, insomnia symptoms were 
seen in 42%: 34.6% reported excessive daytime sleepiness, 
and insomnia symptoms and daytime sleepiness were not 
correlated. Subjects with insomnia only had better cogni-
tive and physical function than those without insomnia (no 
insomnia or daytime dysfunction or daytime dysfunction 
only), and those with daytime dysfunction only had worse 
cognitive and physical function than those without daytime 
dysfunction (Table 4).72 Therefore, it would appear from 
this study that insomnia is associated with better cognitive 
and functional performance, whereas daytime somnolence 
appears to correlate with reduced physical and cognitive 
function. The reasons for this are not known, and additional 
study is needed to replicate this finding. The authors question 
the focus on reducing insomnia and indicate that a greater 
focus on daytime somnolence may be advocated, since it may 
be a surrogate marker for other medical conditions related 
to increased mortality.72
Health care resource utilization
Treatment costs
In the aforementioned US-based survey of managed-care 
organizations (n = 3447), insomnia was significantly associ-
ated with increased health care resource.35 Compared with 
individuals with normal sleep, patients with sleep complaint 
plus daytime dysfunction (resulting from sleep disturbance) 
had significantly greater consumption of OTC and prescribed 
medications and laboratory tests, resulting in higher treat-
ment costs than those with unsatisfactory sleep alone. The 
treatment costs of those individuals with sleep problems 
alone were also higher than in those individuals without 
insomnia.35
visits to health care professionals
Results from the study by Hatoum et al further showed that 
when compared with individuals with normal sleep and 
those with sleep problems alone, patients with insomnia and 
daytime dysfunction had increased physician visits or tele-
phone contact with their physician and more frequent visits 
to the emergency department.35 Again, patients with sleep 
disturbance alone had a greater number of visits to health 
care professionals than those with no insomnia.35
Hospitalizations
A French study designed to estimate the medical and socio-
professional consequences of insomnia compared a group of 
severe insomniacs with a matched group of good sleepers 
in the general population. Patients with severe insomnia Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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were hospitalized more often (18 versus 9%; P = 0.0017), 
particularly for gastrointestinal problems (33 versus 11%; 
P value not stated), and spent a longer duration in hospital 
than those individuals classified as good sleepers (1.19 versus 
0.76 days; P = NS).17
In a population cohort of .10,000 women, the use of 
sleep medication, but not sleep impairment, was significantly 
associated with increased risk of falls, physician consul-
tations, and days in hospital, following adjustment for 
confounding factors.20 These findings suggest that it is the 
sleeping medication use, in addition to the sleep impairment, 
that plays a significant contributing role to the overall human 
and economic burden.
Absenteeism/presenteeism
We identified no studies specified as studying comorbid 
insomnia and its impact on insomnia, sick leave, or work 
performance. However, as discussed in the primary insom-
nia section, the study by Leger et al52 probably included a 
substantial proportion of patients with comorbid insomnia 
and found approximately double the rate of absenteeism in 
insomnia sufferers versus good sleepers.52
Population-based studies
Several large population-based cohorts have demonstrated 
that patients with insomnia have greater impairment of 
HR-QOL than good sleepers (Table 4),20,72,74–76 and that the 
degree of impairment has a linear relationship with severity 
of insomnia.75
Evaluation of a cohort of Australian women aged 
70–75 years confirmed the high prevalence of insomnia.20 
A total of 63% of women experienced sleeping difficulties 
at baseline and this correlated with lower QOL, specifically 
reduced physical and social functioning, bodily pain, and 
general mental health.20
In a cross-sectional analysis of more than 3400 patients 
with chronic illness, severe and mild insomnia were reported 
in 16% and 34% of study patients, respectively. Insomnia 
was shown to be independently associated with a significant 
decrease in overall QOL for patients with chronic illness, 
and the magnitude of this decrease for those with severe 
insomnia was comparable with that observed in patients 
with chronic conditions, such as congestive heart failure 
or depression.74
Recent studies
Among studies published since we conducted our litera-
ture review, one publication reported the association of 
  insomnia with HR-QOL, work productivity, and activity 
impairment.85 Data were obtained from the 2005 US 
National Health and Wellness Survey with subjects assigned 
to either the insomnia group (ie, insomnia experienced at 
least a few times a month; n = 5161) or a control group (no 
insomnia or sleep symptoms; n = 14,550). HR-QOL was 
assessed using the short-form 8 (SF-8) (mental and physical 
scores), with absenteeism (work time missed), presentee-
ism (impairment at work), work productivity loss (overall 
work impairment), and activity impairment assessed using 
the work productivity and activity impairment instrument 
(WPAI). Subjects in the insomnia group had significantly 
lower SF-8 physical (-5.40) and mental (-4.39) scores and 
greater activity impairment scores (+18.04) than those in 
the control group (P , 0.01 for all). In addition, greater 
absenteeism (+6.27), presenteeism (+13.20), and work 
productivity loss (+10.33) scores were reported for those 
employed in the insomnia group than the control group 
(P , 0.01 for all).85
Another recent study in 2009 by Nebes et al examined 
the relation between sleep quality and cognitive performance 
in community-based older adult volunteers with substantial 
variability in sleep quality. Controlling for common medical 
comorbidities or medication usage, good and poor sleepers 
differed on tests of working memory, attentional set shifting, 
and abstract problem solving but not on processing speed, 
inhibitory function, or episodic memory. Poor sleepers had 
increased depressive symptomatology such as decreased 
concentration, but not for mood (eg, sadness). The authors 
suggested that in certain cognitive domains only, sleep prob-
lems may contribute to performance variability in elderly 
individuals.86
One final article was identified that assessed the associa-
tion between insomnia and daytime functioning. Ustinov 
et al in 2010 assessed data from a study of 734 volunteers 
(235 individuals who reported chronic insomnia and 
499 individuals who reported no sleep problems) from a 
community sample in Memphis, Tennessee. Participants 
completed a 2-week sleep diary, a battery of daytime func-
tioning instrument (the Beck Depression Inventory, the 
State-Trait Anxiety Inventory, ESS, the IIS, and the Fatigue 
Severity Scale), and a medical disorders checklist. Using 
a hierarchical regression model, the authors showed that 
insomnia was a significant predictor of reduced functioning 
on all five daytime functioning measures. Moreover, reports 
of insomnia were able to account for most of the variability 
in self-reported daytime functioning. The authors concluded 
that individuals’ perceptions of their sleep were related to Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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differences in their reported daytime functioning, which 
may be related to a set of common cognitive factors caus-
ing distress with sleep and increasing dissatisfaction with 
daytime functioning.87
Discussion
It is clear from this review of baseline clinical study data 
that untreated primary insomnia, specifically poor sleep 
quality and reduced daytime functioning, is associated 
with substantial costs to both society as a whole and to 
individuals. Costs can be associated directly through reduced 
QOL, impairment of cognitive and physical functioning, and 
the subsequent increase in health care resource utilization 
associated with these problems, and indirectly as a result 
of reduced work productivity/presenteeism, lost income/
absenteeism, and other sources of indirect burden on society 
such as an increased risk of vehicle crashes. However, data 
on the impact of primary insomnia on absenteeism are incon-
sistent; in the absence of depression, a common comorbidity 
in insomnia, absenteeism rates may be no higher than in 
those without insomnia.
Studies indicate that comorbid insomnia is also associ-
ated with substantial costs additional to those associated 
with the primary disorder, its treatment, and the side effects 
of treatment. However, many comorbid insomnia studies 
evaluating the impact on QOL and resource utilization do 
not clearly differentiate comorbid insomnia from treatment-
related side effects or do not separate the costs due to specific 
effects of insomnia and those due to the primary disorder, 
its treatment, and adverse effects, and more research is 
required to identify and evaluate specific costs in these 
patients. There is a basic problem with studies of insomnia 
in that a large proportion of patients included in the studies 
actually have insomnia comorbid to an underlying condi-
tion and, therefore, it is extremely difficult to tease out the 
costs specific to insomnia alone from those relating to the 
primary condition.
This manuscript provides a comprehensive consideration 
of the ‘downstream’ effects of insomnia on both individuals 
and society. Building upon some excellent recent in-depth 
reviews in insomnia by Kyle et al, Shekleton et al, and Léger 
and Bayon, this article attempts to evaluate the data on QOS 
and daytime functioning in untreated insomnia as well as 
the relationship of insomnia symptoms to HR-QOL, direct 
resource utilization, and indirect costs.88–90 However, it should 
be noted that most diagnosed insomnia is treated either 
using CBT or pharmacotherapy, and this treatment is itself 
associated with substantial direct and indirect costs. Robust 
pharmacoeconomic cost-effective models are required to 
ascertain whether the costs of treatment are outweighed by 
the cost savings associated with improved QOS, daytime 
function, and QOL.
In view of the inconsistency of assessment scales in this 
field, further development and validation of sleep assess-
ment tools, with the aim of producing a standardized set 
of diagnostic and assessment scales, are pivotal to gaining 
a more accurate assessment of the true societal burden of 
insomnia and impaired QOS and daytime functioning. Such 
tools will enable researchers to compare data from interven-
tion studies, thus contributing to a greater understanding of 
this disorder.
Data on the impact of both primary and comorbid insomnia 
on QOL demonstrate that treatment options for insomnia 
should aim to improve not only the sleep deficits, includ-
ing poor sleep quality, but also the daytime functioning, 
QOL deficits, and psychomotor and cognitive impairment. 
As studies have shown, these aspects of insomnia are not 
interdependent, but are all strongly associated with burden 
of illness in the individual and will exert a marked influence 
on the utilization of health care resources from a societal 
perspective.
In conclusion, insomnia, both primary and comorbid, 
is the source of substantial cost to both the individual and 
society. Comorbid insomnia is by far the more common 
disorder. Given the overlapping resource utilization and 
indirect effects that can be ascribed to more than one fac-
tor in patients with comorbid insomnia, it is extremely 
difficult to separate the costs attributable to the primary 
disorder from those attributable to insomnia alone. Even 
studies claiming to be in patients with primary insomnia 
may include a high proportion of patients whose insomnia 
is associated with an underlying condition. For a more 
accurate estimation of costs related to insomnia, studies 
are needed which control for the severity of the primary 
disorder. Currently, most of the available data are from 
the United States and so data from other countries are also 
needed for comparison.
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